SENOMAC: Omitting Completion Axillary Dissection Maintains Survival and Reduces Arm Morbidity in Breast Cancer
The SENOMAC trial results indicate that omitting completion axillary lymph node dissection in breast cancer patients with limited sentinel node involvement does not compromise survival. This approach significantly reduces long-term arm morbidity for patients.
Why it matters
These findings represent a major shift in surgical oncology, potentially improving the quality of life for breast cancer survivors by reducing unnecessary invasive procedures.
SENOMAC: Omitting Completion Axillary Dissection Maintains Survival and Reduces Arm Morbidity in Breast Cancer - OncoDaily
The article provides a technical, evidence-based summary of a medical trial without subjective framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in